Title: Optimizing the treatment regimen for targeted alpha therapy of mCRPC with 225Ac-PSMA-617
Authors: KRATOCHWIL CLEMENSRATHKE HBRUCHERTSEIFER FRANKGIESEL FREDERIKHABERKORN UWEMORGENSTERN ALFRED
Citation: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 45 no. S1 p. S54
Publisher: SPRINGER
Publication Year: 2018
JRC N°: JRC111747
ISSN: 1619-7070 (online)
URI: http://publications.jrc.ec.europa.eu/repository/handle/JRC111747
DOI: 10.1007/s00259-018-4148-3
Type: Articles in periodicals and books
Abstract: PSMA-targeting alpha-therapy (PSMA-TAT) of mCRPC with 225Ac-PSMA-617 (8 MBq, 3 cycles, 8 week intervals) already demonstrated promising anti-tumor activity, but also induced severe and often irreversible xerostomia (1,2). Our objective was to optimize the treatment protocol to improve tolerability.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.